Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer

Head and Neck

Volumn 35, Issue 10, 2013, Pages 1471-1474

  Bossi, Paolo ^a   Kornek, Gabriela ^b   Lanzetta, Gaetano ^c   Rozzi, Antonio ^d   Füreder, Thorsten ^b   Locati, Laura ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c IRCCS NEUROMED   (Italy)

^d Istituto Neurotraumatologico Italiano   (Italy)

Author keywords

every other week cetuximab; maintenance therapy; quality of life; recurrent and or metastatic head and neck cancer

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CENTER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHARYNX CANCER; LARYNX CANCER; MAINTENANCE CHEMOTHERAPY; METASTASIS; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; OROPHARYNX CANCER; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT CANCER;

EVERY-OTHER-WEEK CETUXIMAB; MAINTENANCE THERAPY; QUALITY OF LIFE; RECURRENT AND/OR METASTATIC HEAD AND NECK CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; ITALY; MAINTENANCE CHEMOTHERAPY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SAFETY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884904170     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23170     Document Type: Article

References (15)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL,. Head and neck cancer. Lancet 2008; 371: 1695-1709.
2. Grégoire V, Lefebvre JL, Licitra L, Felip E,. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (suppl 5): v184-v186.
3. Ko C, Citrin D,. Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis 2009; 15: 121-132.
4. Ang KK,. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist 2008; 13: 899-910.
5. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27.
6. Pignon JP, le Maitre A, Bourhis J,. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69 (suppl 2): S112-S114.
7. Psyrri A, Kwong M, DiStasio S, et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 2004; 22: 3061-3069.
8. Vermorken JB, Mesía R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
9. Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21: 1967-1973.
10. Tabernero J, Pfeiffer P, Cervantes A,. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008; 13: 113-119.
11. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B,. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19: 1141-1145.
12. Mrabti H, De la Fouchardiere C, Desseigne F, Dussart S, Negrier S, Errihani H,. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J Cancer Res Ther 2009; 5: 272-276.
13. Rogers SN, Harvey-Woodworth CN, Hare J, Leong P, Lowe D,. Patients' perception of the financial impact of head and neck cancer and the relationship to health related quality of life. Br J Oral Maxillofac Surg 2012; 50: 410-416.
14. Guntinas-Lichius O, Ruhlow S, Veelken F, Klussmann JP,. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 2009; 135: 901-908.
15. Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011; 16: 228-238.